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Executive summary
Background
After a stroke, around one-third of people experience persisting problems with aphasia or 
dysarthria, limiting their ability to communicate through speech, writing or gesture. This restricts 
everyday activities and social participation, has adverse psychological effects and negatively 
impacts on families. Early, regular and intensive therapy may capitalise on brain plasticity, 
augmenting the natural recovery observed in the first few months.
The impact of speech and language (SL) therapy for this population is unknown owing to an 
absence of robust research evidence. In 2002, the UK’s National Institute for Health Research 
(NIHR) identified the need to evaluate the clinical effectiveness and cost-effectiveness using 
therapy that was likely to be feasible for routine NHS delivery and comparing this with an 
attention control (AC), i.e. patient contact but not specific therapy.
Aim
The ACT NoW (Assessing the effectiveness of Communication Therapy in the North West) study 
was commissioned by the NIHR Health Technology Assessment programme and began with 
a feasibility study followed by a definitive study of the clinical effectiveness, cost-effectiveness 
and service user and carer views of an early well-resourced flexible communication intervention 
delivered by SL therapists, compared with an equivalent amount of contact but not therapy 
provided by employees badged as ‘visitors’. This aimed to examine whether there is an added 
benefit of early SL therapy over and above a combination of natural recovery and receiving 
regular empathic attention.
Design
Extensive feasibility work was completed (2004–6), including the development of novel outcome 
measures. The definitive study (2006–10) consisted of a multicentre, parallel-group randomised 
controlled trial (RCT), economic evaluation and qualitative study. Randomisation was by an 
independent trials service. Primary analysis compared groups on 6-month outcomes using an 
intention-to-treat approach. Cost-effectiveness, cost-effectiveness acceptability analysis and net 
benefit analyses were used to relate costs and outcomes and explore the value for money of SL 
therapy, including a survey to determine societal preferences for waiting time and outcomes. The 
qualitative study used individual interviews with a subset of trial participants to explore service 
users’ and carers’ perceptions of process and outcome. Collaborative working partnerships 
with two groups were central to the design and conduct of this study: a research user group 
of service users (‘the RUG’) and a visionary group of NHS SL therapists willing to take on this 
challenging study.
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Setting
The study was based in 12 NHS stroke services in England. Recruitment took place during 
the inpatient phase. Interventions were delivered across the stroke pathway (hospital 
and community).
Participants
The NHS SL therapists screened over 2000 people admitted with stroke with possible 
communication problems and considered one-fifth to be eligible for the trial on the grounds that 
they were likely to benefit from the research intervention. Exclusion criteria were pragmatic (out 
of area, unable to communicate in English) or clinical [therapy deemed unsuitable (e.g. pre-
existing dementia, learning difficulties) for end-of-life care, serious health (including cognitive) 
problems, global communication problems or, alternatively, communication problems resolved 
or likely to without intervention].
One hundred and seventy people were randomly allocated to SL therapy (85) or AC (85), a 
consent rate of 44% of those invited. RUG-developed, aphasia-friendly consent materials proved 
useful in maximising trial participation. Participants ranged in age from 32 to 97 years (mean 
70 years) and 56% were men. Almost all had aphasia (90%), 39% had dysarthria and 29% had 
both. Half were classified as having a severe activity restriction (disability) in terms of their 
baseline communication, suggesting that the sample included the full range from mild to severe. 
Half had dysphagia (impaired swallowing).
Some people declined follow-up, resulting in 81 and 72 cases, respectively, available for analysis 
in the SL and AC groups. The economic evaluation examined data from the trial participants in 
addition to a survey returned by 278 members of the public. Twenty-two trial participants and 
10 carers took part in the qualitative study. Carers also participated in the RCT (n = 135). They 
were typically female family members in the same household, not in paid employment and were 
younger than the stroke participants.
Intervention and control treatments
The SL therapy was a consensus-based, best practice, flexible intervention developed by NHS SL 
therapists for delivery in usual care settings, but better resourced. This allowed commencement 
as soon as clinically indicated and, if required, up to three contacts per week for up to 16 weeks, 
following participants across their stroke pathway. Adherence to the therapy manual was ensured 
through inspection of written records, observation of delivery and regular peer group meetings.
The study found that therapy was delivered as intended, flexibly tailored to individual need and 
on average started 2 weeks after stroke, involved 22 contacts (18 hours) delivered over 13 weeks, 
in both hospital and community settings. Half of the activities coded were direct intervention. 
Forty-two per cent of contacts were delivered by therapists of Band 7/8. Therapists sometimes felt 
that it was too early for an individual to engage intensively and 43% were referred for continuing 
NHS SL therapy after the study.
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Attention control was offered at the same intensity by employed visitors who did not provide 
therapy or any communication strategies. Visitors had excellent social skills and general 
competency and were trained to deliver social attention absent of any intuitive form of 
communication therapy or strategy. They followed a manual allowing everyday activities (e.g. 
conversation, TV, music), but visits were mostly led by participants. Visitors were monitored to 
ensure adherence to the protocol.
Main outcome measures
The primary outcome was functional communicative ability 6 months post randomisation, 
rated on the activity subscale of the Therapy Outcome Measure activity subscale (TOM) by a 
blinded independent SL therapist. Secondary outcomes were participants’ perceptions of their 
own functional communication and quality of life on the Communication Outcomes After 
Stroke scale (COAST); carers’ perceptions of participants’ functional communication using 
the first 15 questions on the Carer COAST; carers’ own quality of life with the relevant five 
questions from the Carer COAST; and carer ‘well-being’ using the Carers of Older People in 
Europe (COPE) Index. Serious adverse events (SAEs) were recorded (deaths, further stroke, 
readmission to hospital). For the economic evaluation participants completed the European 
Quality of Life-5 Dimensions (EQ-5D) health status questionnaire and service use data were 
collected from medical records at 6 months and from carers. Preferences for different outcomes 
of communication therapy and willingness to wait for therapy were measured by a discrete choice 
survey completed by members of the public.
Results
External validity was good. Those who participated were similar in their measured characteristics 
to those who declined. Internal validity was also good. The control group had more disability at 
baseline but this was adjusted for in sensitivity analyses.
Speech and language therapy services struggled with staffing the intervention but overall 
succeeded in providing the intended (early but flexible) intervention at an average amount that 
was higher than most NHS services. Most importantly, they provided continuity by following 
participants across the stroke pathway, whereas in usual care they would be placed on waiting 
lists following transfer to the community. There was high uptake of both therapy and control 
visits by service users. This was slightly lower for the latter, reflecting patient choice; however, 
an adequate control was provided. An observational comparison of TOM activity scores at 
baseline and 6 months suggested a clinically meaningful level of improvement in functional 
communication of 0.8 points [95% confidence interval (CI) 0.6 to 1.0 points] regardless of 
group allocation.
Primary analysis estimated a difference of 0.25 (95% CI –0.19 to 0.69) points on the primary 
outcome (TOM) in favour of SL therapy. Sensitivity analyses suggested that this estimated 
difference was due to the imbalance in baseline severity and the imputation of values for deaths. 
Per-protocol analyses rejected a possible dilution of therapy from the 18 control participants 
who rejected their allocation and received some NHS SL therapy. These findings appear robust 
and exclude the possibility of a clinically significant difference of 0.5 on the TOM in either 
direction. There was also no evidence of an added benefit of SL therapy on any of the secondary 
outcomes, including patient- and carer-reported measures. There was no statistically significant 
difference in SAEs between the groups [odds ratio of 0.42 (95% CI 0.16 to 1.1)]. Although SAEs 
were less frequent in the therapy group, they were rare (15 vs 7). Subgroup analyses (by aphasia 
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vs dysarthria or by level of severity of communication impairment) produced no evidence of a 
differential subgroup effect.
The likely cost-effectiveness of therapy was at the upper end of the acceptable willingness-to-pay 
thresholds of the National Institute for Health and Clinical Excellence. However, there were 
several limitations to the economic evaluation and primary and sensitivity analyses indicated a 
high level of uncertainty, suggesting that it is not possible to conclude whether therapy is more or 
less cost-effective than AC.
The qualitative study found that, regardless of whether they saw a visitor or an SL therapist, 
participants highly regarded this experience, which made a positive impact on their lives. The 
amount of contact and the interpersonal skills/personal qualities of the person providing it 
(visitor or SL therapist ) were identified as important drivers for recovery that built confidence 
and developed a positive mood. Users believed that an important mechanism for recovery of 
communicative ability and growing awareness of residual disability was repeated practice of 
everyday communicative activities with a professional who showed empathy and interest in their 
individual needs. Carers expressed strongly positive views about the support that survivors had 
received, whether from the visitor or SL therapist. They identified the importance not just of 
regular contact, but of that contact coming from someone outside of the survivor’s family/social 
milieu. The outsider provided interaction and communication opportunities that challenged 
the person they cared for in ways they could not because it forced an engagement with the 
unfamiliar. Carers did not identify any primary benefit to themselves, but rather secondary 
benefits from seeing the survivor make progress.
Conclusions
The ACT NoW study provides robust evidence and a definitive answer to a clinically important 
question, with good generalisability of its findings. Functional communicative ability at 6 months 
had improved by a clinically meaningful amount for people in both groups. However, there was 
no evidence of an added benefit of early communication therapy from SL therapists for people 
with communication disability or their carers over and above that from AC and natural recovery, 
when both were provided at a higher level than in typical standard practice. Therefore, there 
is no evidence to recommend enhancing the provision of early communication therapy by a 
qualified SL therapist over and above usual care, and the evidence suggests that the latter should 
be reorganised.
To determine whether the benefits were due to therapy rather than time with a therapist, both 
groups were offered early and well-resourced time. Service users valued the early and frequent 
contact from professional visitors/therapists outside of their family and friends who showed 
interest in their individual needs. These impacted positively on their confidence and mood, 
providing repeated practice of everyday communication. In terms of clinical implications, the 
study did not evaluate the early role of SL therapists after stroke. Much of SL therapists’ early 
workload is for the assessment and treatment of dysphagia and in usual practice communication 
and swallowing are managed together. We evaluated one aspect (communication therapy), and 
only after a diagnosis had been made and provided to the user, family and multidisciplinary team 
(MDT), thereby precluding conclusions about the value of diagnosis by an SL therapist.
Less definitive were the results on adverse events and the economic evaluation. There remains 
the possibility that therapy reduced the rate of deaths, further strokes and rehospitalisation and 
this may have warranted further research had a mechanism been established (i.e. had therapy 
improved communication), which it was not. Early enhanced SL therapy for communication is 
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likely to be cost-effective only if decision-makers are prepared to pay ≥ £25,000 to gain one unit 
of utility. However, uncertainty over cost-effectiveness is of no practical concern given the lack of 
evidence of clinical effectiveness.
There may be divided opinion over whether AC was the most suitable choice for this study. 
Uncertainty over the relative contribution of natural recovery versus the early, regular attention 
provided by therapists or visitors would have been eliminated by a no-contact control. There 
were two good reasons for not commissioning this. First, if therapy proved more effective (as 
most people expected) it would remain unknown whether the active mechanism was the therapy 
or the psychosocial effect of providing attention. Second, it is highly unlikely that a no-contact 
control trial would have been feasible given ethical concerns and lack of equipoise for clinicians 
and potential participants.
An alternative control would have been usual care. Assuming an effect along a continuum for 
therapy per se as opposed to attention, with usual care theoretically in between the two ACT 
NoW groups, our finding of no difference between the two extremes would be replicated when 
comparing the extreme and midpoint.
Recommendations for research
Research should assess a reorganised SL therapy communication service that uses a stepped 
care model of intervention considering skill mix and timing. SL therapists’ early role could 
be around diagnosis, communicating this to the user and MDT and supervising assistants for 
regular visits similar to those provided for the AC group in ACT NoW. Intervention would later 
step up to direct SL therapist contact for those with persisting need and include the part of the 
stroke pathway referred to as Life After Stroke. Usual care by NHS SL therapists would be an 
appropriate comparator.
Further research should investigate whether the ACT NoW SL therapy was delivered too soon in 
the stroke pathway, by evaluating its effectiveness with a chronic clinical population, those with 
persisting communication problems months and years post stroke. There is huge unmet need 
in this population yet considerable uncertainty about service delivery and an understandable 
tendency to assign scarce resources to those in the first 6 months of recovery. A future study 
would challenge the unlikely but sometimes cited suggestion that recovery is only possible in the 
short term.
Specific promising interventions should be subjected to RCTs, for example conversation partner 
training. Therapy for people with dysarthria is a neglected area of stroke rehabilitation research, 
warranting investigation. Aphasia research must be generalisable to the target population, 
including people without English as their first language.
Future economic evaluation needs to find ways of capturing valid baseline EQ-5D data from 
acutely ill and communication-impaired participants and of ensuring sufficient resources to chase 
missing data from incomplete or inaccessible NHS records.
Trial registration
This trial is registered as ISRCTN78617680.
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